Mary Caffrey

ASCO: City of Hope investigator highlights mosunetuzumab plus polatuzumab vedotin ADC/bispecific combo boosting PFS in LBCL with manageable adverse events outpatient.

McKesson and The US Oncology Network find EOM attribution often mislabels cancer episodes—especially oral therapy—threatening value-based care accuracy and accountability.

Real-world ASCO data link GLP-1 drugs to markedly longer survival across common cancers, raising new questions on mechanism and trials.

Cardinal Health hires ex-FCS leader Nathan Walcker to drive The Specialty Alliance's growth, including managed services in gastroenterology and urology.

The lead investigator for SUCCESSOR-2 discusses the potency of a potential successor to pomalidomide in treatment of multiple myeloma, with survival outcomes that rival CAR T-cell therapy.

Although smaller studies have highlighted CAR T differences in access and outcomes, new research shows the full extent of the issue.

The bispecific T-cell engager could fulfill an unmet need among patients with mantle cell lymphoma who progress after treatment with a BTK inhibitor.

On paper, the OCM cost Medicare millions. A decade later, physicians say its lessons are priceless.

Remote therapeutic monitoring with ePROs powered by AI cuts hospitalizations and boosts therapy time—now a key oncology leader promotes guidelines and reimbursement to make it standard of care.

Canopy remote therapeutic monitoring with ePROs cuts hospitalizations and extends time to discontinuation in metastatic cancer, saving millions.

Data presented at ASCO support wider use of prophylactic therapy to prevent cytokine release syndrome as efforts expand to promote bispecifics in treatment of multiple myeloma.

Data confirm the use of daratumumab, bortezomib, lenalidomide, and dexamethasone as the standard of care in newly diagnosed multiple myeloma.

An entirely new approach to treating one of the most intractable cancers could turn it into a chronic disease.

Adding the anti-CD19 monoclonal antibody and lenalidomide to the classic combination drove superior PFS, with a positive trend in OS. Higher rates of adverse events offset the positive survival results in an area of great unmet need.

Early data for LINKER-AL2 show linvoseltamab drives rapid and deep responses following relapse after frontline treatment for AL amyloidosis, which has no approved therapies.

Teclistamab bispecific from Johnson & Johnson boosts early-line multiple myeloma outcomes, fueling safer outpatient therapy options.

Mezigdomide, a powerful CELMoD, doubles PFS in relapsed or refractory multiple myeloma, offering hope when IMiDs stop working.

ASCO 2026 spotlights practice-changing cancer data: PROTEUS in prostate cancer, RAS(ON) inhibitor daraxonrasib, new bispecifics, and GLP-1 signals.

An Institute for Value-Based Medicine® event in Princeton highlights how the state's leading cancer care providers meet the needs of a diverse population.

ASCO highlights MorningSun results: subcutaneous mosunetuzumab offers a chemotherapy-free option for elderly patients with DLBCL, improving quality of life beyond R-CHOP.

Analyses to be presented at ASCO show zanubrutinib offers improved survival benefits and longer time to the next treatment over another BTK inhibitor in 2 common indications.

Johnetta Blakely, MD, MS, MMHC, discusses her new role as chief medical officer of the Community Oncology Alliance during an interview that will appear in the June issue of Evidence-Based Oncology.

Ontada research presented at ISPOR 2026 shows the NCCN Distress Thermometer can predict overall survival in metastatic cancers, but the relationship varies by cancer type.

Ontada finds that EHR-based education boosts NCCN guideline-concordant care for patients with HER2-low metastatic cancer, raising targeted treatment use among providers who took part in the education activities.

A CLL caregiver shares the reality of CAR T-cell therapy and why support for those who play this critical role will be essential to ensure access to these therapies.

US News & World Report reveals caregivers—often sandwich generation—face full-time hours, rising costs, burnout; CareYaya weighs in on demographics.

The next-generation BCL2 inhibitor is approved for adults with relapsed or refractory MCL who have received at least 2 lines of systemic treatment

The complexity of MCL calls for personalized therapeutic strategies, but prior authorization protocols may not recognize distinct patient needs.

Epcoritamab added to R2 sharply boosts follicular lymphoma responses, but infection risks and real-world feasibility raise tough treatment decisions.